Jie Wu

University of Oklahoma

H指数:52

被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The impact of preoperative carbohydrate ingestion one hour before surgery on children's preoperative anxiety and postoperative pain under ultrasound monitoring: A randomized controlled trial

术前碳水化合物摄入（手术前一小时）对儿童术前焦虑和术后疼痛的影响（在超声监测下）：一项随机对照试验

Journal of Clinical Anesthesia

IF5.1

2025-10-100

PREAI

Characterization of T-cell immune responses against Staphylococcus chromogenes naturally-induced subclinical mastitis in dairy cows

自然诱导的奶牛亚临床型金黄色葡萄球菌乳腺炎的T细胞免疫应答特征

Frontiers in Immunology

IF5.9

2025-10-100

OAAI

Identification of alkynyl nicotinamide HSN748 as a RET solvent-front mutant inhibitor with intracranial efficacy

HSN748作为RET溶剂前沿突变体抑制剂的鉴定及其颅内疗效

RSC Med. Chem.

IF3.6

2025-08-220

Targeting CK2 eliminates senescent cells and prolongs lifespan in Zmpste24-deficient mice

CELL DEATH & DISEASE

IF9.6

2024-05-302

OAAI

Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer

在RET驱动的癌症中对选择性RET抑制的适应性达尔文脱靶抗性机制

NPJ PRECISION ONCOLOGY

IF8

2024-03-047

OAAI

RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond

重组RET抑制剂普拉斯替尼治疗ESR1融合阳性乳腺癌及其他

CANCER RESEARCH

IF16.6

2023-10-021

PRE

Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors

ANNALS OF ONCOLOGY

IF65.4

2023-10-011

OAAI

Progress and challenges in RET-targeted cancer therapy

FRONTIERS OF MEDICINE

IF3.5

2023-05-0312

PRE

The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases

对RET激酶抑制剂的抗性的异质过渡态收敛于ERK1/2驱动的Aurora A/B激酶

DRUG RESISTANCE UPDATES

IF21.7

2023-05-016

OAAI

Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors

MOLECULAR CANCER THERAPEUTICS

IF5.5

2023-04-187

Loss of Bif-1 suppresses Bax/Bak conformational change and mitochondrial apoptosis

MOLECULAR AND CELLULAR BIOLOGY

IF2.7

2023-03-27195

OAAI

Role of Gab1 in UV-induced c-Jun NH2-terminal kinase activation and cell apoptosis

MOLECULAR AND CELLULAR BIOLOGY

IF2.7

2023-03-2725

OAAI

RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives

RET异常癌症和RET抑制剂治疗: 当前的最新技术和未来的观点

PHARMACOLOGY & THERAPEUTICS

IF12.5

2023-02-0116

OAAI

Comprehensive analysis of the prognostic value and immune infiltration of FGFR family members in gastric cancer

FRONTIERS IN ONCOLOGY

IF3.3

2022-09-068

OAAI

Precision therapy for RET-altered cancers with RET inhibitors

TRENDS IN CANCER

IF17.5

2021-12-01103

OAAI

Absolute quantification of 2-hydroxyglutarate on tissue by matrix-assisted laser desorption/ionization mass spectrometry imaging for rapid and precise identification of isocitrate dehydrogenase mutations in human glioma

INTERNATIONAL JOURNAL OF CANCER

IF4.7

2021-09-042

OAAI

The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib

NPJ PRECISION ONCOLOGY

IF8

2021-06-0738

OAAI

Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer

ANNALS OF ONCOLOGY

IF65.4

2021-06-0130

OAAI

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations

ANNALS OF ONCOLOGY

IF65.4

2021-02-01153

OAAI

Whole brain radiotherapy (WBRT) for leptomeningeal metastasis from NSCLC in the era of targeted therapy: a retrospective study

RADIATION ONCOLOGY

IF3.2

2020-07-3125

OAAI

Jie Wu

个人简介

教育背景

工作经历

荣誉奖项

研究方向